Introduction of Clesrovimab (Enflonsia) as an additional product for RSV passive immunisation in at-risk infants (WHC/2026/029)

Guidance for NHS Wales health professionals on the use of Clesrovimab (Enflonsia) as an additional product for passive immunisation against respiratory syncytial virus (RSV) in at-risk infants.

Part of:

Health circulars: 2024 to 2027,
Infections (Sub-topic),
Maternity and early years (Sub-topic),
Respiratory disease (Sub-topic) and
Vaccination (Sub-topic)

First published:

31 July 2026

Last updated:

31 July 2026

Documents

Introduction of Clesrovimab (Enflonsia) as an additional product for RSV passive immunisation in at-risk infants (WHC/2026/029)

Introduction of Clesrovimab (Enflonsia) as an additional product for RSV passive immunisation in at-risk infants (WHC/2026/029) , HTML

HTML

Documents

Introduction of Clesrovimab (Enflonsia) as an additional product for RSV passive immunisation in at-risk infants (WHC/2026/029) , HTML

First published

Last updated

Part of

Share this page